A treatment-resilient lipid remodeling program links autophagy flux failure to temozolomide resistance in glioblastoma

Abstract Temozolomide (TMZ) resistance remains a major barrier to effective glioblastoma therapy and is increasingly linked to metabolic adaptation and cellular stress responses. In this study, we investigated the relationship between autophagy dysregulation and cholesterol metabolism during glioma progression and TMZ resistance. Tissue microarray analysis of astrocytoma and glioblastoma specimens showed a grade-associated increase in LC3β puncta and FDPS expression, supporting an association between altered autophagy-related vesicle accumulation and cholesterol biosynthetic remodeling in higher-grade gliomas. To explore this relationship mechanistically, TMZ-resistant U251 glioblastoma cells were generated and compared with TMZ-sensitive counterparts. Resistant cells exhibited epithelial-to-mesenchymal transition–like morphology, reduced proliferation, mitotic quiescence, mitochondrial remodeling, and diminished respiratory reserve capacity, consistent with a therapy-tolerant metabolic phenotype. Ultrastructural and biochemical analyses revealed persistent autophagosome accumulation and impaired autophagy flux in resistant cells. This defect was accompanied by suppression of de novo cholesterol biosynthesis, reduced total cholesterol, expression of SREBP-2 and LDL-R, and extensive remodeling of cholesterol ester species identified by lipidomic profiling. Although inhibition of the mevalonate pathway with simvastatin altered cholesterol ester composition, it failed to restore TMZ sensitivity or induce apoptosis in resistant cells. Together, these findings indicate that persistent autophagy flux impairment and altered cholesterol metabolism characterize TMZ-resistant glioblastoma.

Authors

Institutions

Publication Details

Journal
Cell Death Discovery
Published
2026-11-16
DOI
https://doi.org/10.1038/s41420-026-03375-6
Primary Topic
Autophagy in Disease and Therapy
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A treatment-resilient lipid remodeling program links autophagy flux failure to temozolomide resistance in glioblastoma

Rui Miguel Pinheiro Vitorino, Donald W. Miller, Mehdi Eshraghi, Sanjiv Dhingra et al.
1 links
Cell Death Discovery
Autophagy in Disease and Therapy
article

A treatment-resilient lipid remodeling program links autophagy flux failure to temozolomide resistance in glioblastoma

Rui Miguel Pinheiro Vitorino, Donald W. Miller, Mehdi Eshraghi, Sanjiv Dhingra, Grant Michael Hatch, Amir Ravandi, Mateusz M. Tomczyk, Mahmoud Aghaei, Vinith Yathindranath, Christopher D. Pascoe, Shahla Shojaei, Saeid Ghavami, Stevan Pecic, Laura Cole, Basso Joao, Tania Dehesh, Zeinab Babaei, Javad Alizadeh, Bhavya Bhushan, Kianoosh Naghibzadeh, Simone CDS Rosa, Roham Saberi, Amir Barzegar Behrooz, Vernon W. Dolinsky, Abhay Srivastava, Negar Azarpira, Courtney Clark
article en

Abstract

Abstract Temozolomide (TMZ) resistance remains a major barrier to effective glioblastoma therapy and is increasingly linked to metabolic adaptation and cellular stress responses. In this study, we investigated the relationship between autophagy dysregulation and cholesterol metabolism during glioma progression and TMZ resistance. Tissue microarray analysis of astrocytoma and glioblastoma specimens showed a grade-associated increase in LC3β puncta and FDPS expression, supporting an association between altered autophagy-related vesicle accumulation and cholesterol biosynthetic remodeling in higher-grade gliomas. To explore this relationship mechanistically, TMZ-resistant U251 glioblastoma cells were generated and compared with TMZ-sensitive counterparts. Resistant cells exhibited epithelial-to-mesenchymal transition–like morphology, reduced proliferation, mitotic quiescence, mitochondrial remodeling, and diminished respiratory reserve capacity, consistent with a therapy-tolerant metabolic phenotype. Ultrastructural and biochemical analyses revealed persistent autophagosome accumulation and impaired autophagy flux in resistant cells. This defect was accompanied by suppression of de novo cholesterol biosynthesis, reduced total cholesterol, expression of SREBP-2 and LDL-R, and extensive remodeling of cholesterol ester species identified by lipidomic profiling. Although inhibition of the mevalonate pathway with simvastatin altered cholesterol ester composition, it failed to restore TMZ sensitivity or induce apoptosis in resistant cells. Together, these findings indicate that persistent autophagy flux impairment and altered cholesterol metabolism characterize TMZ-resistant glioblastoma.

Cell Death Discovery
Isfahan University of Medical Sciences (IR), California State University, Fullerton (US), Shiraz University (IR), Universidade do Porto (PT), Shiraz University of Medical Sciences (IR), Guilan University of Medical Sciences (IR), Kerman University of Medical Sciences (IR), St. Boniface Hospital (CA), CancerCare Manitoba (CA), Children's Hospital Research Institute of Manitoba (CA), Akademia Śląska (PL), LAQV Requimte (PT), University of Manitoba (CA), University of Aveiro (PT), University of Coimbra (PT)
Research Manitoba, CancerCare Manitoba Foundation, Children's Hospital Research Institute of Manitoba, Canadian Institutes of Health Research, Fundação para a Ciência e a Tecnologia
Good health and well-being
Autophagy in Disease and Therapy
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon